Ultra-long-acting insulin: a new chapter in diabetes therapy?
- 4 October 2024
- journal article
- editorial
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 12 (11) , 777-779
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1The Lancet Diabetes & Endocrinology, 2024
- Continuous Glucose Monitoring–Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4Diabetes Care, 2024
- Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous InsulinNew England Journal of Medicine, 2023
- Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosingBMJ Open Diabetes Research & Care, 2021
- Time in range: A best practice guide for UK diabetes healthcare professionals in the context of the COVID‐19 global pandemicDiabetic Medicine, 2020
- InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring—Study DesignDiabetes Therapy, 2020
- Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in RangeDiabetes Care, 2019
- Validation of Time in Range as an Outcome Measure for Diabetes Clinical TrialsDiabetes Care, 2018
- The Fallacy of Average: How Using HbA1c Alone to Assess Glycemic Control Can Be MisleadingDiabetes Care, 2017
- Factors associated with injection omission/non‐adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy studyDiabetes, Obesity and Metabolism, 2012